Alto Neuroscience, Inc. ((ANRO)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Alto Neuroscience, Inc. is conducting a clinical study titled Double-Blind, Placebo-Controlled Study of ALTO-101 in Patients With Schizophrenia and Cognitive Impairment. The study aims to evaluate the efficacy of ALTO-101T in improving cognitive processing markers and cognition in patients with schizophrenia. This research is significant as it explores potential treatments for cognitive impairments associated with schizophrenia, a condition that affects millions globally.
Intervention/Treatment: The study tests ALTO-101T, a transdermal delivery system designed to administer the drug ALTO-101. This intervention aims to enhance cognitive function in patients with schizophrenia by altering cognitive processing markers measured via EEG.
Study Design: This Phase 2 study employs a randomized, double-blind, placebo-controlled, two-way crossover design. Participants receive both the ALTO-101T and a placebo in random order, with a washout period between treatments. The study is quadruple-masked, meaning neither participants nor researchers know who receives the actual treatment, ensuring unbiased results.
Study Timeline: The study began on July 9, 2024, with its primary completion and estimated overall completion dates yet to be announced. The latest update was submitted on October 20, 2025. These dates are crucial for investors tracking the progress and potential market entry of ALTO-101T.
Market Implications: The ongoing study of ALTO-101T could significantly impact Alto Neuroscience’s stock performance, especially if results demonstrate efficacy in treating cognitive impairments in schizophrenia. Positive outcomes may enhance investor sentiment and position Alto Neuroscience as a leader in this niche market. Competitors in the neurological treatment space will be closely monitoring these developments.
The study is currently ongoing, with further details available on the ClinicalTrials portal.